Skip to main content
Clinical Trials/EUCTR2012-000512-29-ES
EUCTR2012-000512-29-ES
Active, Not Recruiting
N/A

Sonothrombolysis potentiated by microbubbles as a novel treatment of acute ischemic stroke: a prospective randomized pilot study - SONOVUE

Institut de Recerca Hospital Sant Pau0 sitesApril 17, 2012
DrugsSONOVUE

Overview

Phase
N/A
Intervention
Not specified
Conditions
Not specified
Sponsor
Institut de Recerca Hospital Sant Pau
Status
Active, Not Recruiting
Last Updated
10 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 17, 2012
End Date
TBD
Last Updated
10 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Institut de Recerca Hospital Sant Pau

Eligibility Criteria

Inclusion Criteria

  • The main inclusion criteria will be:
  • \- All acute (\<4,5 hours) ischemic stroke patients in the MCA territory (as depicted by head computed tomography CT or suspected by clinical data) with a disabling neurological deficit measurable by National Institute of Health Stroke Scale (NIHSS) score, that in the opinion of treating physicians require and meet accepted criteria of treatment with a standard 0\.9mg/kg dose of iv rtPA.
  • \- A documented occlusion of the middle cerebral artery (MCA) documented by TCD and/or angioCT.
  • \-The patient or the legal representative signs the written consent to participate
  • \-Age ? 18 years
  • \-No significant improvement before treatment.
  • \-The treatment is initiated within 90 minutes of hospital admission (door\-to\-needle time ? 90 minutes)
  • \-There is no limitation regarding the NIHSS score. Scores under 5 are usually considered mild strokes, but they can be treated if the investigator believes that the measured deficit is important enough to cause disability. The investigator should weight benefits and risks when the score is under 5 and above 22\.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:

Exclusion Criteria

  • Patients will be excluded if they have 1 or more of the following:
  • \-severe stroke as indicated on baseline CT imaging or by a NIHSS score \> 25
  • \-evidence of hemorrhage on noncontrast head computed tomography CT),
  • \-any other standard contraindication for intravenous rtPA therapy,
  • \-primary treatment with intra\-arterial thrombolysis,
  • \-Previous Rankin scale score \> 1 and NIHSS \< 14 or previous Rankin scale score \>2 and NIHSS ? 14
  • \- Rapidly improving neurological symptoms such that the rate of improvement is expected to result in a NIHSS score of \<4 at randomization
  • \- Coexisting neurological diseases such as dementia or life\-threatening illness.
  • \- Seizure at symptom onset
  • \- History or clinical presentation of intracranial hemorrhage, subarachnoid hemorrhage (even with a normal CT), arteriovenous malformation, aneurysm, spinal cord disease or cerebral neoplasm. Incidental meningioma and microbleeds per se are not exclusion criteria.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 2
Sonothrombolysis Potentiated by Microbubbles for Acute Ischemic StrokeCerebrovascular Stroke
NCT01678495Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau24
Recruiting
N/A
Safety and Efficacy of sonolysis therapy for treatment of microvascular damage after myocardial infarctioMyocardial infarctionHartinfarct
NL-OMON28497VU University Medical Center20
Active, Not Recruiting
N/A
OR-SASS is a multi-centre PROBE (prospective randomised, open-label, blinded endpoint) trial, designed to establish the superiority of contrast-enhanced sonothrombolysis given within 4½ hours after stroke onset in consecutively admitted patients with acute ischaemic stroke, as compared with 1) standard iv thrombolysis with tenecteplase (TNK) or alteplase (tPA), and 2) no specific treatment in patients not eligible for thrombolytic treatment.All patients found eligible for thrombolysis may enter the thrombolysis-arm (NOR-SASS I), all patientswith contraindications to thrombolysis within the 4 ½ hour time window may enter the no-thrombolysis-arm(NOR-SASS II).MedDRA version: 14.1Level: PTClassification code 10061256Term: Ischaemic strokeSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]
EUCTR2012-000323-41-NOHelse Bergen, Haukeland University Hospital
Recruiting
N/A
Blood clot dissolution with echocardiogram as initial treatment in acute ST elevation myocardial infarctioHealth Condition 1: I21- Acute myocardial infarction
CTRI/2020/04/024888Christian medical college and hospital vellore
Completed
N/A
Sonolysis in Risk Reduction of Symptomatic and Silent Brain Infarctions During Coronary StentingCoronary Artery Disease
NCT02351050University Hospital Ostrava144